OnQ rts® FDA Cleared to Market in North America

Posted on Jan 10, 2013

Oncology Systems Ltd., an innovative medical technology company focused on delivering leading edge technologies into the radiotherapy workplace, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its OnQ rts® clinical imaging workflow software. When working with the demands of IG/IMRT and CT/PET/MR imaging in radiotherapy, OnQ rts addresses departmental needs by offering a multi-faceted platform that enhances patient throughput and reduces formerly manual processes to free user’s time.

OnQ rts software automates complex tasks for auto-contouring, deformable image registration and contour analysis in radiation therapy and medical imaging. OnQ saves time.

OnQ provides clinical review and verification tools for evaluating multi-modality fused images, multiple RT dose plans, adaptive re-planning, contour accuracy and for comparing daily transit exit dose with planned dose. OnQ builds confidence

OSL's Managing Director, Carl Pavey, commented; "We are very excited about the introduction of this new product in the USA. The OnQ rts adds to our ImSimQA™ image quality assurance software already available in North America and we believe it provides an exceptional tool in the fight against cancer."

OSL News

Oncology Systems Ltd brings together all the latest news about radiotherapy in the UK.

For all the latest Oncology Systems company articles, take a look at OSL news

This page was printed from OSL Web site at http://www.osl.uk.com